Long-Acting Reversible Contraceptives Await “Obamacare” Boost
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Contraception coverage mandated by the Affordable Care Act could unlock demand for IUDs. Actavis aims to provide an alternative to Bayer’s hormone-eluting IUD in 2014; public sector rights to Levosert are assigned to nonprofit Medicines360.
You may also be interested in...
Nonprofit Medicines360 Provides Affordable Contraception, Women’s Health
Emerging Company Profile: Medicines360 and partner Allergan launched the IUD Liletta in 2015, so now the nonprofit pharmaceutical company is looking for additional contraceptives and women’s health products.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.